Skip to main content
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd - Investor Relations & Filings

Listed IPO Jul 2021
Ticker · RGC ISIN · KYG7487R1002 US Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2023-06-05 Regulatory Filings
Country US United States of America
Listing US RGC · 3 venues

About Regencell Bioscience Holdings Ltd

https://www.regencellbioscience.com/

Regencell Bioscience Holdings Ltd. is an early-stage bioscience company that focuses on the research, development, and commercialization of proprietary Traditional Chinese Medicine (TCM) formulations. The company's primary therapeutic focus is on treating neurocognitive and neurodevelopmental disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). It aims to develop natural and effective treatments to improve the quality of life for patients and their families, with the goal of becoming a global market leader in this field.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It announces a lock-up undertaking by directors and employees regarding stock options, extending the lock-up period. The document is relatively short (2123 characters) and primarily serves as an announcement rather than a detailed financial report or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It also does not fit into categories like Annual Report, Interim Report, or Earnings Release. The content is regulatory in nature, reporting a corporate action related to insider share lock-up. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Regencell Bioscience Holdings Limited, with the SEC. It reports a change in the company's certifying accountant and includes a letter from the previous auditor. The document does not contain financial statements or detailed financial data but rather disclosures about auditor changes and confirmations. It is not an annual or interim report, nor an earnings release. The document is regulatory in nature, providing compliance information about auditor changes and related disclosures. Given the content and the nature of Form 6-K filings, this fits best under Regulatory Filings (RNS). The document length is 4018 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2023-03-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Regencell Bioscience Holdings Limited, submitted to the SEC. It announces the appointment of a new Chief Business Officer, detailing the individual's background and promotion. There are no financial statements, earnings data, or detailed management discussion of financial results. The document is short (2936 characters) and focuses solely on management change. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). Therefore, the appropriate classification is MANG with high confidence.
2023-02-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains information about a lock-up agreement for directors and employees related to stock options, with no financial statements or detailed financial data. The document length is 2309 characters, which is relatively short and primarily serves as an announcement of a lock-up undertaking rather than a full financial report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. The content is regulatory in nature, reporting a corporate governance-related lock-up agreement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-01-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an announcement about the resignation of the Chief Medical Officer and related management changes. There are no financial statements, detailed financial data, or comprehensive reports included. The document is relatively short (2650 characters) and primarily serves as a regulatory announcement about management changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2022-12-22 English
ANNUAL REPORT
Annual Report FY 2022
2022-10-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.